A detailed history of Grassi Investment Management transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Grassi Investment Management holds 18,000 shares of FATE stock, worth $41,220. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,000
Previous 18,000 -0.0%
Holding current value
$41,220
Previous $59,000 6.78%
% of portfolio
0.01%
Previous 0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 11, 2023

BUY
$4.24 - $11.12 $76,320 - $200,160
18,000 New
18,000 $103,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Grassi Investment Management Portfolio

Follow Grassi Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grassi Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Grassi Investment Management with notifications on news.